Media ReleasesImmutep

View All Immutep News


Immutep Announces Australian Patent Granted For Eftilagimod Alpha In Chemo-Immunotherapy

SYDNEY, AUSTRALIA – 21 June 2019 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 2014368420) entitled “Combined Preparations for the Treatment of Cancer” by the Australian Patent Office.

This Australian patent follows the recent grant of the corresponding European patent (announced 23 May 2019) and protects Immutep’s intellectual property relating to combined therapeutic preparations
comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a chemotherapy agent. The chemotherapy agent is either a platinum-based anti-neoplastic agent, such as
oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.

For further information please download the attached PDF:
Download this document